Update on the Clinical Management of Atrial Fibrillation: Guidelines and Beyond

References

• . Go AS, Hylek EM, Phillips KA, . Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18):2370–2375
   PubMed Web of Science ®Google Scholar
• . Fuster V, Ryden LE, Cannom DS, . 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011; 57(11): e101–e198
   PubMed Web of Science ®Google Scholar
• . Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104(11):1534–1539
   PubMed Web of Science ®Google Scholar
• . Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: Clinical implications. J Am Coll Cardiol. 2001; 37(2):371–378
   PubMed Web of Science ®Google Scholar
• . Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull. 2008; 88(1):75–94
   PubMed Web of Science ®Google Scholar
• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991; 22(8):983–988
   PubMed Web of Science ®Google Scholar
• . Dorian P, Mangat I, Pinter A, Korley V. The burden of atrial fibrillation: Should we abandon antiarrhythmic drug therapy? J Cardiovasc Pharmacol Ther. 2004; 9(4):257–262
   PubMed Web of Science ®Google Scholar
• . Valderrama AL, Dunbar SB, Mensah GA. Atrial fibrillation: Public health implications. Am J Prev Med. 2005; 29(5 suppl 1):75–80
   PubMed Web of Science ®Google Scholar
• . Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly patients: Pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther. 2007; 81(2):284–287
   PubMed Web of Science ®Google Scholar
• . Wann LS, Curtis AB, January CT, ; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123(1):104–123
   PubMed Web of Science ®Google Scholar
• . ; European Heart Rhythm Association; European Association for Cardio-Thoracic SurgeryCamm AJ, Kirchhof P, Lip GY, . Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369–2429
   PubMed Web of Science ®Google Scholar
• . Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines. 2010. http://www.ccsguidelineprograms.ca/index.php?option=com_content&view=article&id=112%3Aafib-executive-summary&catid=50&Itemid=66. Accessed July 13, 2011
   Google Scholar
• . The National Collaborating Centre for Chronic Conditions. Atrial Fibrillation National Clinical Guideline for Management in Primary and Secondary Care. London, UK: Royal College of Physicians; 2006
   Google Scholar
• . Snow V, Weiss KB, LeFevre M, . Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003; 139(12):1009–1017
   PubMed Web of Science ®Google Scholar
• . Kim MH, Lin J, Hussein M, Battleman D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin. 2009; 25(5):1215–1220
   PubMed Web of Science ®Google Scholar
• . Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy. 2009; 29(12):1417–1426
   PubMed Web of Science ®Google Scholar
• . Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007; 370(9587):604–618
   PubMed Web of Science ®Google Scholar
• . Bjerregaard P, Bailey WB, Robinson SE. Rate control in patients with chronic atrial fibrillation. Am J Cardiol. 2004; 93(3):329–332
   PubMed Web of Science ®Google Scholar
• . Camm J. Medical management of atrial fibrillation: State of the art. J Cardiovasc Electrophysiol. 2006; 17( suppl 2):S2–S6
   Web of Science ®Google Scholar
• . Fang MC, Chen J, Rich M W. Atrial fibrillation in the elderly. Am J Med. 2007; 120(6):481–487
   PubMed Web of Science ®Google Scholar
• . Dell'Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of atrial fibrillation: Spontaneous conversion rates and cost of care. Am J Cardiol. 1999; 83(5):788–790, A10
   PubMed Web of Science ®Google Scholar
• . Danias PG, Caulfield TA, Weigner MJ, Silverman DI, Manning WJ. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998; 31(3):588–592
   PubMed Web of Science ®Google Scholar
• . Naccarelli GV, Wolbrette DL, Khan M, . Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol. 2003; 91(6A):15D–26D
   Web of Science ®Google Scholar
• . Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011; 27(1):74–90
   PubMed Web of Science ®Google Scholar
• . Flaker GC, Belew K, Beckman K, . Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149(4):657–663
   PubMed Web of Science ®Google Scholar
• . Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98(5):476–484
   PubMed Web of Science ®Google Scholar
• . Kimura K, Minematsu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005; 76(5):679–683
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Padanilam BJ, Prystowsky EN. Atrial fibrillation: Goals of therapy and management strategies to achieve the goals. Cardiol Clin. 2009; 27(1):189–200
   PubMed Web of Science ®Google Scholar
• . Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57(2):173–180
   PubMed Web of Science ®Google Scholar
• . Fang MC, Go AS, Chang Y, . A new risk scheme to predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011; 58(4):395–401
   PubMed Web of Science ®Google Scholar
• . Thosani AJ, Xiong Y, Lin J, Kothawala P, Zimetbaum PJ. Are atrial fibrillation patients receiving anticoagulation in accordance with their stroke risk? Abstract PO06-60. Presented at the Heart Rhythm Society; May 13–16, 2009; Boston, MA
   Google Scholar
• . Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997; 28(12):2382–2389
   PubMed Web of Science ®Google Scholar
• . Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000; 160(1):41–46
   PubMedGoogle Scholar
• . Cohen N, Almoznino-Sarafian D, Alon I, . Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission. Stroke. 2000; 31(6):1217–1222
   PubMed Web of Science ®Google Scholar
• . Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J. 1999; 137(2):307–312
   PubMed Web of Science ®Google Scholar
• . Gage BF, Boechler M, Doggette AL, . Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000; 31(4):822–827
   PubMed Web of Science ®Google Scholar
• . Leckey R, Aguilar EG, Phillips SJ. Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol. 2000; 16(4):481–485
   PubMed Web of Science ®Google Scholar
• . McCormick D, Gurwitz JH, Goldberg RJ, . Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001; 161(20):2458–2463
   PubMedGoogle Scholar
• . Samsa GP, Matchar DB, Goldstein LB, . Quality of anticoagulation management among patients with atrial fibrillation: Results of a review of medical records from 2 communities. Arch Intern Med. 2000; 160(7):967–973
   PubMed Web of Science ®Google Scholar
• . Scott PA, Pancioli AM, Davis LA, Frederiksen SM, Eckman J. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke. 2002; 33(11):2664–2669
   PubMed Web of Science ®Google Scholar
• . Hylek EM, Go AS, Chang Y, . Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11):1019–1026
   PubMed Web of Science ®Google Scholar
• . ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet. 2006; 367(9526):1903–1912
   PubMed Web of Science ®Google Scholar
• . ; ACTIVE InvestigatorsConnolly SJ, Pogue J, Hart RG, . Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360(20):2066–2078
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed July 13, 2011
   Google Scholar
• . Wann LS, Curtis AB, Ellenbogen KA, . 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123(10):1144–1150
   PubMed Web of Science ®Google Scholar
• . Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2010
   Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Wallentin L, Connolly SJ, . Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123(21):2363–2372
   PubMed Web of Science ®Google Scholar
• . Janssen Pharmaceuticals, Inc. FDA approves XARELTO (rivaroxaban tablets) to help prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery [press release]. July 1, 2011. http://www.janssenpharmaceuticalsinc.com/assets/xareltopressrelease.pdf. Accessed July 13, 2011
   Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investgators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Jenkins SM, Dunn FG. Key issues in the management of atrial fibrillation—protecting the patient and controlling the arrhythmia. Scott Med J. 2007; 52(3):27–35
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger R W. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I–III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999; 30(6):1223–1229
   PubMed Web of Science ®Google Scholar
• . Prudente LA. Atrial fibrillation (AF) and heart failure (HF): To treat the AF, be sure to treat the HF. Prog Cardiovasc Nurs. 2008; 23(3):146–149
   PubMedGoogle Scholar
• . Wang TJ, Larson MG, Levy D, . Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation. 2003; 107(23):2920–2925
   PubMed Web of Science ®Google Scholar
• . Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010; 41(12):2731–2738
   PubMed Web of Science ®Google Scholar
• . Olesen JB, Lip GY, Hansen ML, . Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ. 2011; 342:d124
   PubMed Web of Science ®Google Scholar
• . Olesen JB, Lip GY, Lindhardsen J, . Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011; 106(4):739–749
   PubMed Web of Science ®Google Scholar
• . Lee G. A review of the literature on atrial fibrillation: Rate reversion or control? J Clin Nurs. 2007; 16(1):77–83
   PubMed Web of Science ®Google Scholar
• . Carlsson J, Miketic S, Windeler J, ; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003; 41(10):1690–1696
   PubMed Web of Science ®Google Scholar
• . Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet. 2000; 356(9244):1789–1794
   PubMed Web of Science ®Google Scholar
• . Opolski G, Torbicki A, Kosior D, . Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol Pol. 2003; 59(7):1–16
   PubMedGoogle Scholar
• . van Gelder I, Hagens VE, Bosker HA, ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347(23):1834–1840
   PubMed Web of Science ®Google Scholar
• . Wyse DG, Waldo AL, DiMarco JP, ; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23):1825–1833
   PubMed Web of Science ®Google Scholar
• . Singh BN, Singh SN, Reda DJ, ; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18):1861–1872
   PubMed Web of Science ®Google Scholar
• . Kim MH, Lin J, Hussein M, Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009; 25(12):3037–3047
   PubMed Web of Science ®Google Scholar
• . Hawkins NM, Petrie MC, Macdonald MR, . Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011; 57(21):2127–2138
   PubMed Web of Science ®Google Scholar
• . McCabe PJ, Geoffroy S. Atrial fibrillation: The newest frontier in arrhythmia management. Prog Cardiovasc Nurs. 2002; 17(33):110–123, 141
   PubMedGoogle Scholar
• . Roberts SA, Diaz C, Nolan PE, . Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol. 1993; 72(7):567–573
   PubMed Web of Science ®Google Scholar
• . Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin. 2004; 22(1):35–45
   PubMed Web of Science ®Google Scholar
• . Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999; 33(2):304–310
   PubMed Web of Science ®Google Scholar
• . Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;(4): CD005049
   Google Scholar
• . Kochiadakis GE, Marketou ME, Igoumenidis NE, . Amiodarone, sotalol, or propafenone in atrial fibrillation: Which is preferred to maintain normal sinus rhythm? Pacing Clin Electrophysiol. 2000; 23(11 pt 2):1883–1887
   PubMed Web of Science ®Google Scholar
• . Ishak KJ, Proskorovsky I, Guo S, Lin J. Persistence with antiarrhythmics and the impact on atrial fibrillation-related outcomes. Am J Pharm Benefits. 2009; 1(4):193–200
   Google Scholar
• . Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998; 98(23):2574–2579
   PubMed Web of Science ®Google Scholar
• . Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation. 2001; 104(3):292–296
   PubMed Web of Science ®Google Scholar
• . Singh SN, Fletcher RD, Fisher SG, . Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995; 333(2):77–82
   PubMed Web of Science ®Google Scholar
• . Multaq [package insert]. Bridgewater, NJ: sanofi-aventis U. S. LLC; 2011
   Google Scholar
• . Cordarone [package insert]. Philadelphia, PA: Wyeth Laboratories; 2004
   Google Scholar
• . Laughlin JC, Kowey PR. Dronedarone: A new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008; 19(11):1220–1226
   PubMed Web of Science ®Google Scholar
• . Hohnloser SH, Crijns HJ, van Eickels M, . Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360(7):668–678
   PubMed Web of Science ®Google Scholar
• . Page RL, Connolly SJ, Crijns HJ, ; ATHENA Investigators. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011; 107(7):1019–1022
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Crijns HJ, Torp-Pedersen C, . Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009; 120(13): 1174–1180
   PubMed Web of Science ®Google Scholar
• . Singh BN, Connolly SJ, Crijns HJ, ; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357(10):987–999
   PubMed Web of Science ®Google Scholar
• . Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol. 2010; 21(6):597–605
   PubMed Web of Science ®Google Scholar
• . Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace. 2011; 13(3):329–345
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration; US Department of Health and Human Services. FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). 2011. http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm. Accessed July 13, 2011
   Google Scholar
• . US Food and Drug Administration. Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between July–September 2010. 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm237585.htm. Accessed March 21, 2011
   Google Scholar
• . The Institute for Safe Medication Practices. QuarterWatch: 2010 Quarter 1. Monitoring MedWatch Reports. Signals for acetaminophen, dronedarone and botulinum toxin products [executive summary]. http://freepdfhosting.com/078147c86d.pdf. Published November 4, 2010. Accessed March 21, 2011
   Google Scholar
• . Kober L, Torp-Pedersen C, McMurray JJ, . Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358(25):2678–2687
   PubMed Web of Science ®Google Scholar
• . Sanofi-aventis initiates 10,000 patient study with Multaq® in permanent AF [press release]. http://www.prnewswire.com/news-releases/sanofi-aventis-initiates-10000-patient-study-with-multaqr-in-permanent-af-93551119.html. Published May 12, 2010. Accessed July 13, 2011
   Google Scholar
• . Sanofiprovides Multaq phase IIIb PALLAS trial update [press release]. http://en.sanofi.com/binaries/20110707_PALLAS_en_tcm28-33021.pdf. Published July 7, 2011. Accessed July 13, 2011
   Google Scholar
• . Cheng J W. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008; 42(4):533–542
   PubMed Web of Science ®Google Scholar
• . Merck & Co Inc. Brinavess (vernakalant) for infusion approved in the European Union for rapid conversion of recent onset atrial fibrillation [press release]. 2010. http://www.merck.com/news-room/news-release-archive/research-and-development/2010_0901.html?WT.svl=content&WT.pi=content+Views. Published September 1, 2010. Accessed July 13, 2011
   Google Scholar
• . Camm AJ, Capucci A, Hohnloser SH, . A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011; 57(3):313–321
   PubMed Web of Science ®Google Scholar
• . Hsu LF, Jais P, Sanders P, . Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004; 351(23):2373–2383
   PubMed Web of Science ®Google Scholar
• . Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: A meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2009; 2(6):626–633
   PubMed Web of Science ®Google Scholar
• . Wilber DJ, Pappone C, Neuzil P. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA. 2010; 303(4):333–340
   PubMed Web of Science ®Google Scholar
• . Jais P, Packer DL. Ablation vs. drug use for atrial fibrillation. Eur Heart J. 2007; 9( suppl G):G26–G34
   Web of Science ®Google Scholar
• . Cappato R, Calkins H, Chen SA, . Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005; 111(9):1100–1105
   PubMed Web of Science ®Google Scholar
• . Lee G, Sparks PB, Morton JB, . Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: Results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol. 2011; 22(2):163–168
   PubMed Web of Science ®Google Scholar
• . Smit MD, van Gelder IC. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther. 2009; 7(7):763–778
   PubMedGoogle Scholar
• . Dorian P, Singh BN. Upstream therapies to prevent atrial fibrillation. Eur Heart J. 2008; 10( suppl H):H11–H31
   Web of Science ®Google Scholar